- feeds
- popular
- recent
- reader
- about
- story
- technologies
- what is rss
- connect
- dmca
- contact
- Feed Preview HCPLIve articles
Discussing Delirium During Hospitalization with Sharon K. Inouye, MD, MPH
In this interview at the ACP conference, Inouye discussed some of the major reasons for her presentation titled ‘Delirium During Hospitalization.’
https://www.hcplive.com/view/discussing-delirium-during-hospitalization-sharon-inouye-md-mph
Study Investigates Optimal COVID-19 Vaccination Timing in Inflammatory Disease
Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.
Elna Saah, MD: Unraveling the Current Landscape in Sickle Cell Disease
Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.
https://www.hcplive.com/view/elna-saah-md-unraveling-current-landscape-sickle-cell-disease
GPT-4 Nears "Expert-Level" Performance in Ophthalmology Examination
Modern large language models perform strongly on ophthalmic knowledge assessments and approach or exceed the scores of fully qualified and trainee ophthalmologists.
https://www.hcplive.com/view/gpt-4-nears-expert-level-performance-ophthalmology-examination
REDUCE-IT Analysis Outlines Benefit of Icosapent Ethyl Across Range of LDL-C Levels
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
Budesonide Maintains IgA Nephropathy Kidney Failure Reduction, Quality of Life at 2 Years
New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.
SGLT2 Inhibitors Reduce Risk of New Gout Diagnoses in T2D Relative to Sulfonylurea
A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remi...
Pharmacy-Based Intervention Linked to Reduced Proton Pump Inhibitor Overuse
A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.
SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events
Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.
https://www.hcplive.com/view/smart-c-meta-analysis-sglt2-inhibitors-reduce-cardiovascular-events
Treating Dry Eye in The Presence of Ocular Comorbidities
Experts discuss the management of dry eye in the presence of concurrent ocular conditions, as well as managing dry eye before undergoing cataract and refractive surgery.
https://www.hcplive.com/view/treating-dry-eye-inthe-presence-of-ocular-comorbidities
Survey Finds Many Fibromyalgia Patients Finding Symptom Relief with Medical Cannabis
Almost 50% of fibromyalgia patients use cannabis for symptom relief, according to new study. Experts suggest results underline need for clinician awareness, further research.
2022 Spike in “Deaths of Despair” Among Black Population Surpasses White People
A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.
DAA Use Increased After State Medicaid Programs Eased HCV Treatment Restrictions
The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.
NSAIDs Decrease the Odds of Adverse Cardiovascular Events in Gout
NSAID use decreased the odds of a cardiovascular event by 12% in patients with gout.
https://www.hcplive.com/view/nsaids-decreased-the-odds-of-adverse-cardiovascular-events-in-gout
Self-Monitoring of Urate Concentration Could Benefit Gout Management
Patient-led urate monitoring supports adherence to urate-lowering therapy and helps attain target concentrations among individuals with gout.
https://www.hcplive.com/view/self-monitoring-urate-concentration-benefit-gout-management
Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.
Visual Impairment Associated with Heightened Risk of Suicidal Tendencies
Vision issues were linked to an increased risk of suicidal ideation, suicidal behavior, and suicide death, particularly among adolescents.
https://www.hcplive.com/view/visual-impairment-associated-heightened-risk-suicidal-tendencies
Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development
In this analysis, investigators sought to assess PsA development probability in subclinical PsA as well as to characterize symptoms and patterns of subclinical PsA.
Plant-Based Diet Intervention Improves Disease Activity, Symptoms in RA, Osteoarthritis
Participants described the intervention as complete and coherent and would recommend this intervention to other patients.
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg
A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.
https://www.hcplive.com/view/secukinumab-300-mg-may-improve-psa-or-active-psoriasis-more-than-150-mg
International Consensus Statement Calls for Prioritization of Kidney Disease by the WHO
The consensus calls for the recognition of kidney disease as a major non-communicable disease driver of premature mortality by the World Health Organization.
No Association Identified Between COVID-19, Development of Asthma Among Children
This analysis looked at the potential connection between SARS-CoV-2 test positivity and new asthma diagnoses.
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.
https://www.hcplive.com/view/insight-on-the-promising-52-week-karxt-data-with-rishi-kakar-md
Tirzepatide Shows Benefit in Obstructive Sleep Apnea, SURMOUNT-OSA Trial
Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.
https://www.hcplive.com/view/tirzepatide-shows-benefit-in-obstructive-sleep-apnea-surmount-osa-trial
TNF Inhibitors Linked to Greater Risk of Progressive eGFR Decline in Patients with IBD
Incident use of anti-TNF therapy was linked to an increased risk of kidney function decline but not all-cause mortality in patients with newly diagnosed IBD.
FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA
The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
https://www.hcplive.com/view/fda-approves-ustekinumab-aekn-for-pso-psa
Analysis Suggests Causal Link Between AMD, Rheumatoid Arthritis
Mendelian randomization analysis demonstrated a direct connection between rheumatoid arthritis and an increased risk of age-related macular degeneration.
https://www.hcplive.com/view/analysis-suggests-causal-link-between-amd-rheumatoid-arthritis
Tocilizumab-aazg Officially Launches in the US for Chronic Autoimmune Diseases
Fresenius announced the immediate availability of its tocilizumab biosimilar, tocilizumab-aazg (Tyenne), in the US.
Treat-and-Extend Regimen Superior in First Year of DME Treatment
A proactive treat-and-extend protocol yields superior results with fewer visits than a less intensive regimen in the first year of treatment for DME.
https://www.hcplive.com/view/treat-and-extend-regimen-superior-first-year-dme-treatment